Patients with severe pulmonary hypertension (PH) and chronic obstructive pulmonary disease (COPD) can now be identified using three widely available clinical variables, all of which can be measured ...

Please provide your email address to receive an email when new articles are posted on . The FDA issued a warning in 2019 about serious breathing problems associated with gabapentinoids. The study ...

Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack of knowledge about medications, among other factors, and leads to increased ...

Nutrition is more than just calories, carbohydrates and protein; it can be a powerful tool in managing lung disease and ...

Patients with both chronic obstructive pulmonary disease (COPD) and severe pain are at an almost 40% predicted probability of falling, indicating the potential interaction between the conditions.

Mepolizumab reduces moderate to severe COPD exacerbations in patients with varying blood eosinophil counts and type 2 ...

In May, we reported on positive phase III trial data on dupilumab (Dupixent) for uncontrolled chronic obstructive pulmonary disease, a condition with no approved biologic therapy. In this report, we ...

Chronic obstructive pulmonary disease (COPD) is a group of diseases that affect the lungs. The disease makes it difficult to breath and progressively gets worse. About 15 million Americans have been ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving dupilumab vs. placebo had a significantly lower risk for at least one severe exacerbation.

By Linda Naa Deide AryeeteyCape Town, March 6, GNA – The World Health Organisation (WHO) General Special Envoy on Chronic ...